UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 97

Sortiert nach

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

The Lancet (British edition), 2013-05, Vol.381 (9880), p.1827-1834

2013

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

Journal of bone and mineral research, 2015-02, Vol.30 (2), p.216-224

2015

Link zum Volltext

Verfügbarkeit prüfen

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

The journal of clinical endocrinology and metabolism, 2018-08, Vol.103 (8), p.2949-2957

2018

Link zum Volltext

Verfügbarkeit prüfen

Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double‐blind study of 102 postmenopausal women with distal radial fractures

Journal of bone and mineral research, 2010-02, Vol.25 (2), p.404-414

2010

Link zum Volltext

Verfügbarkeit prüfen

Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend

Journal of bone and mineral research, 2023-04, Vol.38 (4), p.464-470

2023

Link zum Volltext

Verfügbarkeit prüfen

Quality of Life in Sarcopenia and Frailty

Calcified tissue international, 2013-08, Vol.93 (2), p.101-120

2013

Link zum Volltext

Verfügbarkeit prüfen

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

Journal of bone and mineral research, 2003-11, Vol.18 (11), p.1932-1941

2003

Link zum Volltext

Verfügbarkeit prüfen

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis

Journal of bone and mineral research, 2021-04, Vol.36 (4), p.644-653

2021

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia

Aging clinical and experimental research, 2016-02, Vol.28 (1), p.47-58

2016

Link zum Volltext

Verfügbarkeit prüfen

Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial

Clinical orthopaedics and related research, 2016-05, Vol.474 (5), p.1234-1244

2016

Link zum Volltext

Verfügbarkeit prüfen

Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial

Current medical research and opinion, 2019-12, Vol.35 (12), p.2097-2102

2019

Link zum Volltext

Verfügbarkeit prüfen

The Effect of Discontinuing Treatment With Blosozumab: Follow‐up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density

Journal of bone and mineral research, 2015-09, Vol.30 (9), p.1717-1725

2015

Link zum Volltext

Verfügbarkeit prüfen

Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34)

Journal of bone and joint surgery. American volume, 2005-04, Vol.87 (4), p.731

2005

Link zum Volltext

Verfügbarkeit prüfen

Sustained Nonvertebral Fragility Fracture Risk Reduction After Discontinuation of Teriparatide Treatment

Journal of bone and mineral research, 2005-09, Vol.20 (9), p.1507-1513

2005

Link zum Volltext

Verfügbarkeit prüfen

Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption

Bone (New York, N.Y.), 2019-03, Vol.120, p.148-155

2019

Link zum Volltext

Verfügbarkeit prüfen

Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe

Therapeutic innovation & regulatory science, 2024-05, Vol.58 (3), p.505-518

2024

Link zum Volltext

Verfügbarkeit prüfen

Femoral strength in osteoporotic women treated with teriparatide or alendronate

Bone (New York, N.Y.), 2012-01, Vol.50 (1), p.165-170

2012

Link zum Volltext

Verfügbarkeit prüfen

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis

The New England journal of medicine, 2001-05, Vol.344 (19), p.1434-1441

2001

Link zum Volltext

Verfügbarkeit prüfen

Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis

Journal of bone and mineral research, 2007-01, Vol.22 (1), p.149-157

2007

Link zum Volltext

Verfügbarkeit prüfen

Osteosarcoma and Teriparatide?

Journal of bone and mineral research, 2007-02, Vol.22 (2), p.334-334

2007

Link zum Volltext

Verfügbarkeit prüfen

Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women

The New England journal of medicine, 1997-12, Vol.337 (23), p.1641-1647

1997

Link zum Volltext

Verfügbarkeit prüfen

Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy

Journal of bone and mineral research, 2002-01, Vol.17 (1), p.1-10

2002

Link zum Volltext

Verfügbarkeit prüfen

Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice

Bone Reports, 2020-12, Vol.13, p.100291-100291, Article 100291

2020

Link zum Volltext

Verfügbarkeit prüfen

Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study

JBMR plus, 2020-04, Vol.4 (4), p.e10346-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend

Bone Reports, 2019-12, Vol.11, p.100230-100230, Article 100230

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(93)
Mit Volltextzugriff
(76)

Publikationsform

Sprache

Englisch
(97)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(66)
Humans
(56)
Female
(43)
Endocrinology & Metabolism
(37)
Osteoporosis
(33)
Biological And Medical Sciences
(28)
Aged
(26)
Bone Density - Drug Effects
(24)
Middle Aged
(23)
Medical Sciences
(22)
General & Internal Medicine
(21)
Osteoporosis, Postmenopausal - Drug Therapy
(21)
Bone Density Conservation Agents - Therapeutic Use
(18)
Double-Blind Method
(16)
Bone Density
(15)
Bone Mineral Density
(15)
Fractures
(15)
Medicine, General & Internal
(15)
Human Health Sciences
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double‐blind study of 102 postmenopausal women with distal radial fractures

Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend

Quality of Life in Sarcopenia and Frailty

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis

Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia

Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial

Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial

The Effect of Discontinuing Treatment With Blosozumab: Follow‐up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density

Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34)

Sustained Nonvertebral Fragility Fracture Risk Reduction After Discontinuation of Teriparatide Treatment

Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption

Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe

Femoral strength in osteoporotic women treated with teriparatide or alendronate

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis

Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis

Osteosarcoma and Teriparatide?

Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women

Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy

Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice

Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend

Suchergebnisse filtern